The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report: PAX-FOXO1 Influences Survival in RMS
Open accessAbstract
BACKGROUND: Rhabdomyosarcoma (RMS) is divided into two major histological subtypes: alveolar (ARMS) and embryonal (ERMS), with most ARMS expressing one of two oncogenic genes fusing PAX3 or PAX7 with FOXO1 (P3F and P7F, respectively). The Children's Oncology Group (COG) carried out a multi-institutional clinical trial to evaluate the prognostic value of PAX-FOXO1 fusion status. METHODS: Study participants were treated on COG protocol D9803 for intermediate risk ARMS or ERMS using multi-agent chemotherapy, radiotherapy, and surgery. Central diagnostic pathology review and molecular testing for fusion genes were carried out on prospectively collected specimens. Event-free (EFS) and overall survival (OS) at 5 years were correlated with histological subtype and PAX-FOXO1 status. RESULTS: Of 616 eligible D9803 enrollees, 434 cases had adequate clinical, molecular, and pathology data for definitive classification as ERMS, ARMS P3F+ or P7F+, or ARMSn (without detectable fusion). EFS was worse for those with ARMS P3F+ (54%) and P7F+ (65%) than those with ERMS (77%; P < 0.001). EFS for ARMSn and ERMS were not statistically different (90% vs. 77%, P = 0.15). ARMS P3F+ had poorer OS (64%) than ARMS P7F+ (87%), ARMSn (89%), and ERMS (82%; P = 0.006). CONCLUSIONS: ARMSn has an outcome similar to ERMS and superior EFS compared to ARMS with either P3F or P7F, when given therapy designed for children with intermediate risk RMS. This prospective analysis supports incorporation of PAX-FOXO1 fusion status into risk stratification and treatment allocation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066
Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease
Crist, W. M., Anderson, J. R., Meza, J. L., Fryer, C., Raney, R. B., Ruymann, F. B., Breneman, J., Qualman, S. J., Wiener, E., Wharam, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3091 · Cited by 1,087
Self-citationFusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma
Galili, N., Davis, R. J., Fredericks, W. J., Mukhopadhyay, S., Rauscher, F. J., Emanuel, B. S., Rovera, G., & Barr, F. G. (1993) · Nature Genetics · doi:10.1038/ng1193-230 · Cited by 892
Self-citationSorensen, P. H. B., Lynch, J. C., Qualman, S. J., Tirabosco, R., Lim, J. F., Maurer, H. M., Bridge, J. A., Crist, W. M., Triche, T. J., & Barr, F. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.137 · Cited by 742
Self-citationFusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma.
Davis, R. J., D’Cruz, C. M., Lovell, M. A., Biegel, J. A., & Barr, F. G. (1994) · PubMed · Cited by 585
Self-citationRearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma
Barr, F. G., Galili, N., Holick, J., Biegel, J. A., Rovera, G., & Emanuel, B. S. (1993) · Nature Genetics · doi:10.1038/ng0293-113 · Cited by 555
Self-citationWilliamson, D., Missiaglia, E., de Reyniès, A., Pierron, G., Thuille, B., Palenzuela, G., Thway, K., Orbach, D., Laé, M., Fréneaux, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3814 · Cited by 502
Oberlin, O., Rey, A., Lyden, E., Bisogno, G., Stevens, M. C. G., Meyer, W. H., Carli, M., & Anderson, J. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7207 · Cited by 484
Self-citationEncouraging outcome in pediatric oncology patients admitted to the intensive care unit
Poele, E. M. T., Bolt, R. J., de Bont, E. S., Beijer, L., & Albers, M. J. I. J. (2007) · Bristol Research (University of Bristol) · doi:10.1002/pbc · Cited by 385
Arndt, C. A. S., Stoner, J. A., Hawkins, D. S., Rodeberg, D. A., Hayes-Jordan, A. A., Paidas, C. N., Parham, D. M., Teot, L. A., Wharam, M. D., Breneman, J. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3768 · Cited by 380
Self-citation
Cited by
Shern, J. F., Chen, L., Chmielecki, J., Wei, J. S., Patidar, R., Rosenberg, M., Ambrogio, L., Auclair, D., Wang, J., Song, Y. K., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0639 · Cited by 756
Self-citationShah, A. T., Azad, T. D., Breese, M. R., Chabon, J. J., Hamilton, E. G., Straessler, K., Kurtz, D. M., Leung, S. G., Spillinger, A., Liu, H.-Y., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0987 · Cited by 42
Sarcoma care in the era of precision medicine
Wallander, K., Öfverholm, I., Boye, K., Tsagkozis, P., Papakonstantinou, A., Lin, Y., & Haglund de Flon, F. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13717 · Cited by 30
Metadata
- Authors
- Skapek, S. X., Anderson, J., Barr, F. G., Bridge, J. A., Gastier-Foster, J. M., Parham, D. M., Rudzinski, E. R., Triche, T., & Hawkins, D. S.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2013-03-22
- Volume
- 60
- Issue
- 9
- Pages
- 1411-1417
- ISSN
- 1545-5009 (ISSN-L)
- OpenAlex
- W2101405991
- Cited by
- 278
- References
- 22
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report: PAX-FOXO1 Influences Survival in RMS. https://app.cochat.ai/papers/10.1002/pbc.24532
- The paper
- Skapek, S. X., Anderson, J., Barr, F. G., Bridge, J. A., Gastier-Foster, J. M., Parham, D. M., Rudzinski, E. R., Triche, T., & Hawkins, D. S. (2013). PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report: PAX-FOXO1 Influences Survival in RMS. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.24532
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
